Cadi 05

Drug Profile

Cadi 05

Alternative Names: Cadi-05; Immuvac; Leprosy vaccine - National Institute of Immunology; Leprovac; MIP-vaccine-Cadila; Mycidac-C; Mycobacterium indicus pranii heat-killed - Cadila Pharmaceuticals; Mycobacterium w heat-killed - Cadila Pharmaceuticals

Latest Information Update: 08 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institute of Immunology
  • Developer Cadila Pharmaceuticals
  • Class Antituberculars; Attenuated vaccines; Bacteria; Bacterial vaccines; Cancer vaccines
  • Mechanism of Action Desmocollin modulators; Immunostimulants; P38 mitogen-activated protein kinase inhibitors; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Leprosy; Non-small cell lung cancer
  • Phase III Tuberculosis
  • Phase II/III Sepsis
  • No development reported Bladder cancer; Head and neck cancer; Multiple myeloma
  • Discontinued Malignant melanoma; Prostate cancer

Most Recent Events

  • 08 Aug 2018 Phase-III clinical trials in Tuberculosis in India (Intradermal) (Aeras Global Clinical TB pipeline, August 2018)
  • 19 Dec 2013 No development reported - Clinical for Head and neck cancer in India (Intradermal)
  • 19 Dec 2013 No development reported - Preclinical for Multiple myeloma in India (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top